Sales of antihypertensive therapies generate one of the highest returns in the pharmaceutical sector. However, many hypertensive patients don't achieve satisfactory blood pressure control even when current therapies are prescribed in combination. Furthermore, the fact that each type of antihypertensive agent comes with its own drawbacks underscores the need to develop more novel therapies in this area. Hypertension is a new Decision Resources study that explains why the seemingly saturated hypertension market remains open to innovation and evaluates the efforts of key competitors to satisfy the unmet needs in this sector.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION ) Market Share Will Shift with the Emergence of Omapatrilat
Companies with key marketed angiotensin converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (AIIRAs)-including Novartis, Aventis, Merck & Co., and Bristol-Myers Squibb-will be jostling for market- leading position throughout the 2000-2010 forecast period of this study. Merck & Co. had the edge with the top-selling ACEI, enalapril (Vasotec, generics), and the top-selling AIIRA, losartan (Cozaar), but Bristol-Myers Squibb is set to challenge that leadership with its increasingly popular AIIRA irbesartan and its launch of the dual ACEI/neutral endopeptidase inhibitor omapatrilat (Vanlev).
Omapatrilat Will Erode ACEI Sales
Omapatrilat promises the advantages of dual-mode action, enabling greater blood pressure control with a single agent. Trial data has already established that omapatrilat is superior to the ACEI lisinopril in patients with heart failure. Success in other hypertensive populations will depend on resolving concerns about the side-effect incidence of angioedema. Data will be submitted to the FDA from the OCTAVE trial to determine whether or not incidence of angioedema is within acceptable limits. Assuming all safety concerns are allayed, sales of omapatrilat will reach an estimated $1.8 billion in 2010. To realize this potential, Bristol-Myers Squibb will have to put significant effort into the education of community-based physicians. Omapatrilat will compete strongly for market share with other drugs that target the renin angiotensin aldosterone system (RAAS), including AIIRAs and ACEIs. In this fight, AIIRAs will fare better than their ACEI rivals because pharmaceutical companies will market AIIRAs more aggressively to protect their market share.
Hypertension offers invaluable market intelligence for competing in this arena. This study is part of Cardium, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.
Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.
Contact: Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or firstname.lastname@example.org.
In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone), +32.2.351.2347 (fax), or email@example.com. In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone), +81.3.5401.2617 (fax), or firstname.lastname@example.org.
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840
SOURCE: Decision Resources, Inc.
Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553,